BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36453157)

  • 1. Diabetes mellitus impacts on expression of DNA mismatch repair protein PMS2 and tumor microenvironment in pancreatic ductal adenocarcinoma.
    Pan X; Mizukami H; Hara Y; Yamada T; Yamazaki K; Kudoh K; Takeuchi Y; Sasaki T; Kushibiki H; Igawa A; Hakamada K
    J Diabetes Investig; 2023 Jan; 14(1):132-144. PubMed ID: 36453157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic ductal adenocarcinoma with mismatch repair deficiency resected after long-term observation.
    Ogasawara N; Imamura T; Koyama R; Inoshita N; Nakayama A; Hattori D; Ito Y; Sato Y; Tamura T; Hashimoto M
    Clin J Gastroenterol; 2020 Oct; 13(5):959-968. PubMed ID: 32424776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection.
    Otsuka H; Murakami Y; Uemura K; Kondo N; Nakagawa N; Okada K; Seo S; Takahashi S
    J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):421-428. PubMed ID: 32219999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A correlation study of mismatch repair immunohistochemical protein expression of pancreatic solid tumors in cytology cell blocks and matching surgical specimens.
    Teodosescu A; Chan I; Elder J; Wu M
    Diagn Cytopathol; 2021 Jun; 49(6):700-705. PubMed ID: 33615705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 6. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma.
    Ahmad-Nielsen SA; Bruun Nielsen MF; Mortensen MB; Detlefsen S
    Pathol Res Pract; 2020 Jun; 216(6):152985. PubMed ID: 32360245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
    Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.
    Ban X; Mo S; Lu Z; Jia C; Shao H; Chang X; Mao X; Zhang Y; Pang J; Zhang Y; Yu S; Chen J
    Endocrine; 2022 Sep; 77(3):538-545. PubMed ID: 35708896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of immunohistochemical testing for mismatch repair proteins in fine needle aspiration specimens of pancreatic adenocarcinoma.
    Mettman D; Haer E; Olyaee M; Rastogi A; Madan R; O'Neil M; Kelting S; Dennis K; Fan F
    Ann Diagn Pathol; 2020 Aug; 47():151552. PubMed ID: 32570025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population.
    Sini MC; Doro MG; Frogheri L; Zinellu A; Paliogiannis P; Porcu A; Scognamillo F; Delogu D; Santeufemia DA; Persico I; Palomba G; Maestrale GB; Cossu A; Palmieri G
    J Transl Med; 2024 Jan; 22(1):108. PubMed ID: 38280995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 13. Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells.
    Zhao Z; Lin Z; Guo X; Al-Danakh A; He H; Qin H; Ma C; Zhang N; Tan G
    J Immunol Res; 2023; 2023():4311388. PubMed ID: 37050932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases].
    Liu Y; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Zang FL; Qiu ZQ; Sun BC; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):369-375. PubMed ID: 33831997
    [No Abstract]   [Full Text] [Related]  

  • 15. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
    Bajwa-Ten Broeke SW; Ballhausen A; Ahadova A; Suerink M; Bohaumilitzky L; Seidler F; Morreau H; van Wezel T; Krzykalla J; Benner A; de Miranda NF; von Knebel Doeberitz M; Nielsen M; Kloor M
    Exp Mol Pathol; 2021 Oct; 122():104668. PubMed ID: 34302852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.
    Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T
    J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
    Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
    Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
    Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
    J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PMS2 expression decrease causes severe problems in mismatch repair.
    Kasela M; Nyström M; Kansikas M
    Hum Mutat; 2019 Jul; 40(7):904-907. PubMed ID: 30946512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.